Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Receivables (2017 - 2021)

Historic Receivables for Protagonist Therapeutics (PTGX) over the last 5 years, with Q4 2021 value amounting to $1.6 million.

  • Protagonist Therapeutics' Receivables fell 3544.93% to $1.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.6 million, marking a year-over-year decrease of 3544.93%. This contributed to the annual value of $1.6 million for FY2021, which is 3544.93% down from last year.
  • Protagonist Therapeutics' Receivables amounted to $1.6 million in Q4 2021, which was down 3544.93% from $2.6 million recorded in Q3 2021.
  • Over the past 5 years, Protagonist Therapeutics' Receivables peaked at $7.1 million during Q2 2021, and registered a low of $19000.0 during Q2 2017.
  • Moreover, its 5-year median value for Receivables was $2.8 million (2018), whereas its average is $3.1 million.
  • Its Receivables has fluctuated over the past 5 years, first soared by 3068421.05% in 2018, then crashed by 6429.91% in 2019.
  • Protagonist Therapeutics' Receivables (Quarter) stood at $1.9 million in 2017, then surged by 52.29% to $2.9 million in 2018, then surged by 119.17% to $6.3 million in 2019, then tumbled by 61.22% to $2.4 million in 2020, then plummeted by 35.45% to $1.6 million in 2021.
  • Its last three reported values are $1.6 million in Q4 2021, $2.6 million for Q3 2021, and $7.1 million during Q2 2021.